Overview

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic steatohepatitis (NASH) cirrhosis and clinical signs of portal hypertension but without esophageal varices at baseline.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Galectin Therapeutics Inc.